MASSDEVICE ON CALL — Technology giant Samsung (LON:BC94) announced new healthcare features for upcoming models of its Gear smartphone-connected watches, which will include heart rate sensors and the company’s FDA-cleared S Health app.
Cardiovascular
Welcome to MassDevice's Cardiovascular Hub, your resource for the latest news in cardiac implants, structural heart, heart valves, stents and more. Stay informed about the innovations and business news shaping the cardiovascular device industry.
🫀 Narrow your focus with these categories:
Cardiac Implants | Structural Heart | Pulsed-Field Ablation
Here are top cardiology features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):
+ LVADs save lives: So why aren’t more available?
+ How Medtronic uses nitinol to improve the structure and effectiveness of heart devices
+ How Abbott designed the world’s first dual-chamber leadless pacemaker system
+ J&J used RWE for expanded indications — and you can, too
+ 7 cardiology startups you need to know
Latest Cardiology News
St. Jude issues ‘dear colleague’ letter regarding older pacemakers during surgery
Medtronic lands U.S., E.U. wins for miniature cardiac monitor
Study questions TAVI’s effect on quality of life
Admedus gains U.S. clearance for cardiovascular scaffold
Admedus won 510(k) clearance from the U.S. FDA for its CardioCel cardiovascular scaffold.
Perth, Australia and Minneapolis, Minn.-based Admedus is developing implantable regenerative technologies. CardioCel, the company’s 1st product, is a pure collagen, bio-compatible regenerative tissue scaffold.
Boston Scientific lands expanded E.U. approval for WallFlex esophageal stent
Boston Scientific (NYSE:BSX) won expanded CE Mark approval for its WallFlex stent in the European Union, the company announced.
Claret Medical lands FDA OK for U.S. trial of Sentinel cerebral protection device
Claret Medical is clear to launch a pivotal U.S. trial of its Sentinel cerebral protection system, having won FDA approval to evaluate the device in patients undergoing transcatheter aortic valve implantation.
The study is slated to begin in the 1st quarter of 2014 and will involve up to 15 clinical centers, Claret reported.
TAVI: Direct Flow lands $50M through debt financing
California-based medtech company Direct Flow Medical landed $50 million in debt financing, planning on using the new funds to support commercialization of a new transcatheter aortic valve implantation system.
Medtronic looks to overturn $393M heart valve loss to Edwards Lifesciences
Tryton Medical lands added EU stent clearance
Tryton Medical said it won CE Mark approval in the European Union for its side-branch stent to treat left main coronary artery disease.
Durham, N.C.-based Tryton already has European clearance for the side branch stent, but only for treating bifurcated large-vessel lesions. The new approval makes the device the only stent cleared in Europe for the left main indication, according to a press release.
TAVI: Transcatheter Tech. closes valve prosthesis durability testing
German device maker Transcatheter Technologies GmbH said it finished durability-testing Trinity transcatheter aortic valve implantation system.
The company expects Trinity to be “the world’s 1st ‘truly repositionable'” replacement aortic valve. The device was put through 600 million cycles, or around 15 years, of durability testing by an independent lab, which reported that the device far exceeded minimum standards, according to a press release.